NCT03922607 - A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-157 in Healthy Volunteers and in Participants With Chronic Plaque Psoriasis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 11, 2019

Primary Completion Date

April 13, 2021

Study Completion Date

April 13, 2021

Conditions

Psoriasis

Interventions

DRUG

ABBV-157

ABBV-157 will be administered orally as capsule

DRUG

Placebo for ABBV-157

Placebo for ABBV-157 will be administered orally as capsule

Trial Locations (10)

University of Pittsburgh MC /ID# 224699, Pittsburgh

Total Skin and Beauty Derm Ctr /ID# 222593, Birmingham

Acpru /Id# 213639, Grayslake

Center for Clinical Studies - Webster TX /ID# 217352, Webster

PPD PH I Clinical Unit /ID# 213062, Austin

Alliance Dermatology and MOHs /ID# 222622, Phoenix

Dermatology Res. Assoc., CA /ID# 224980, Los Angeles

Providence Clinical Research /ID# 213339, North Hollywood

Anaheim Clinical Trials LLC /ID# 213645, Anaheim

Advanced Medical Research /ID# 216090, Sandy Springs